GHRH receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-05. Anything still debated is marked as such rather than presented as settled.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Racial disparities have been a prominent and contentious aspect of the war on drugs in the US. In 1957, a belief at the time about drug use was summarized by journalist Max Lerner in his work, America as a Civilization: "As a case in point we may take the known fact of the prevalence of reefer and dope addiction in Negro areas. This is essentially explained in terms of poverty, slum living, and broken families, yet it would be easy to show the lack of drug addiction among other ethnic groups where the same conditions apply." The Anti-Drug Abuse Act of 1986 created a 100:1 sentencing disparity in the US for the trafficking or possession of crack when compared to penalties for trafficking of powder cocaine. The bill had been widely criticized as discriminatory against minorities, mostly blacks, who were more likely to use crack than powder cocaine. In 1994, studying the effects of the 100:1 sentencing ratio, the United States Sentencing Commission (USSC) found that nearly two-thirds of crack users were white or Hispanic, while nearly 85% of those convicted for possession were black, with similar numbers for trafficking. Powder cocaine offenders were more equally divided across race. The USSC noted that these disparities resulted in African Americans serving longer prison sentences than other ethnicities. In a 1995 report to Congress, the USSC recommended against the 100:1 sentencing ratio. In 2010, the 100:1 sentencing ratio was reduced to 18:1. Other studies indicated similarly dramatic racial differences in enforcement and sentencing.
=== Cations and carbonylates === The synthesis of ionic carbonyl complexes is possible by oxidation or reduction of the neutral complexes. Anionic metal carbonylates can be obtained for example by reduction of dinuclear complexes with sodium. A familiar example is the sodium salt of iron tetracarbonylate (Na2Fe(CO)4, Collman's reagent), which is used in organic synthesis. The cationic hexacarbonyl salts of manganese, technetium and rhenium can be prepared from the carbonyl halides under carbon monoxide pressure by reaction with a Lewis acid.
Air cargo refers to any goods shipped by air, whereas air freight refers specifically to goods transported in the cargo hold of a dedicated cargo plane. Aircraft were first used to carry mail as cargo in 1911. Eventually manufacturers started designing aircraft for other types of freight as well. There are many commercial aircraft suitable for carrying cargo such as the Boeing 747 and the more prominent An‑124, which was purposely built for easy conversion into a cargo aircraft. Such large aircraft employ standardized quick-loading containers known as unit load devices (ULDs), comparable to ISO containers on cargo ships. ULDs can be stowed in the lower decks (front and rear) of several wide-body aircraft, and on the main deck of some narrow-bodies. Some dedicated cargo planes have a large opening front for loading. Air freight shipments are very similar to LTL shipments in terms of size and packaging requirements. However, air freight or air cargo shipments typically need to move at much faster speeds than 800 km or 497 mi per hour. While shipments move faster than standard LTL, air shipments do not always actually move by air. Air shipments may be booked directly with the carriers, through brokers or with online marketplace services. In the US, there are certain restrictions on cargo moving via air freight on passenger aircraft, most notably the transport of rechargeable lithium-ion battery shipments. Shippers in the US must be approved and be "known" in the Known Shipper Management System before their shipments can be tendered on passenger aircraft.
May 27, 2009: South Africa South Africa entered recession as the global crisis pounded demand for its main exports; GDP shrank 6.4% in the first quarter of 2009 after falling 1.8% in the last quarter of 2008. This is the first recession for South Africa in 17 years. According to forecasts, the South African domestic product is likely to shrink between 1% and 1.5% in 2009.
Sources: en.wikipedia.org
=== Ion funnel === Ion funnels are RF devices which have been used for decades to focus ion currents into narrow beams. In PTR-MS they have been introduced in 2012 by Barber et al. when they presented a PTR-MS setup with a PTR reaction region incorporating an ion funnel. Although the focusing properties of the ion funnel improved the sensitivity of the setup by a factor of >200 (compared to operating in DC only mode, i.e. with the ion funnel turned off) for some compounds, the sensitivities of other compounds were only improved by a factor of <10. That is, because of the highly compound dependent instrumental response one of the main advantages of PTR-MS, namely that concentration values can be directly calculated, is lost and a calibration measurement is needed for each analyte of interest. Furthermore, with this approach unusual fragmentation of analytes has been observed which complicates interpretation of measurement results and comparison between different types of instruments even more. A different concept has been introduced by the company IONICON Analytik GmbH. (Innsbruck, AT) where the ion funnel is not predominantly part of the reaction region but mainly for focusing the ions into the transfer region to the TOF mass spectrometer. In combination with the above-mentioned method of controlling the ion chemistry this enables a considerable increase in sensitivity and thus also an improvement of the detection limit, while keeping the ion chemistry well-defined and thus avoiding problems with quantification and interpretation of the results.
== History == On 28 November 2016, the university came into existence via Haryana Vidhan Sabha legislature. On 18 April 2017, Chief Minister Manohar Lal Khattar's administration renamed it after the Maharana Pratap.
From then, Alicent's party was known as the "greens" and Rhaenyra's supporters were labeled the "blacks". At the great ceremonial tourney on that day, Viserys and Daemon reunited after several years apart, as Daemon handed Viserys his crown from the Stepstones. The reunion lasted only for six months, as Viserys exiled Daemon once again for reasons unclear, though Septon Eustace claims that Daemon had seduced Rhaenyra and took her maidenhead. Viserys attempted to stabilize relations between the blacks and greens through various gatherings and respective apologies to each other, asserting that he loved Rhaenyra and Alicent equally. In 113 AC, Viserys attempted to find a betrothal for Rhaenyra, believing that the time was right for her to marry. Following the advice of his council, Viserys betrothed her to Laenor Velaryon as a way of stabilizing his tense relationship with Lord Corlys Velaryon. Rhaenyra did not want to marry Laenor, but accepted the match when Viserys threatened to change the order of succession should she refuse. The two married in 114 AC, though it is rumored that they never had their marriage consummated as Laenor was rumored to be homosexual. Rhaenyra gave birth to her sons Prince Jacaerys ("Jace"), Prince Lucerys ("Luke"), and Prince Joffrey Velaryon in 114, 115, and 117 AC while Alicent gave birth to her third son Prince Daeron Targaryen in 114 AC, shortly after Jace.
==== Gender and sex bias ==== In 2014, it was announced that the NIH is directing scientists to perform their experiments with both female and male animals, or cells derived from females as well as males if they are studying cell cultures, and that the NIH would take the balance of each study design into consideration when awarding grants. The announcement also stated that this rule would probably not apply when studying sex-specific diseases (for example, ovarian or testicular cancer).
The mass spectrometer is capable of multicollection, meaning up to 5 (NanoSIMS 50) or 7 (NanoSIMS 50 L) masses can be simultaneously detected, from hydrogen to uranium, though with limitations. The relatively large number of masses helps eliminate measurement errors as possible changes in instrumental or sample conditions that may occur in between runs are avoided. The ion beam must either be set to detect negative or positive ions, commonly completed by using a cesium+ or oxygen- beam, respectively. The high mass resolution achievable is particularly relevant to biological applications. For example, nitrogen is one of the most common elements in organisms. However, due to the low electron affinity of the nitrogen atom, the production of secondary ions is rare. Instead, molecules such as CN can be generated and measured. However, due to isotope combinations, such as the isobars 13C14N-, and 12C15N-, nearly identical molecular weights of 27.000 and 27.006 daltons, respectively, will be generated. Unlike other imaging techniques, where 13C14N and 12C15N cannot be independently measured due to nearly identical masses, NanoSIMS can safely distinguish the differences between these molecules allowing isotopic spiking experiments to be conducted.
Sources: en.wikipedia.org
=== Drug-Drug Interaction === Drug-Drug Interaction models explore the impact of interactions between different drugs on their pharmacokinetics or pharmacodynamics. These models help predict the effects of co-administered drugs on each other, aiding in the identification of potential risks and the adjustment of dosages in the presence of multiple medications.
== Sources == This article incorporates text from a free content work. Licensed under Creative Commons Attribution (license statement/permission). Text taken from Late Professor P N Saxena: A teacher of excellence, Rahman, SZ; Khan, RA (Nov 2010), J Pharmacol Pharmacother.
Scott Boatwright, Chief Executive Officer and Board member Adam Rymer, Chief Financial Officer Curt Garner, President, Chief Strategy and Technology Officer Ilene Eskenazi, Chief Legal and Human Resources Officer Jason Kidd, Chief Operating Officer Laurie Schalow, Chief Corporate Affairs Officer Kerry Bridges, Chief Food Safety Officer
Recombinant antibodies are monoclonal antibodies generated in vitro using synthetic genes. Recombinant antibody technology involves recovering the antibody genes from the source cells, amplifying and cloning the genes into an appropriate vector, introducing the vector into a host, and achieving expression of adequate amounts of functional antibody. Recombinant antibodies can be cloned from any species of antibody-producing animal, if the appropriate oligonucleotide primers or hybridization probes are available. The ability to manipulate the antibody genes make it possible to generate new antibodies and antibody fragments, such as Fab fragments and scFv in vitro. This can be done at the level of the whole combining site by making new combinations of H and L chains. It can also be done by mutating individual CDRs. Display libraries, commonly expressed in phage or yeast, can be analysed to select for desirable characteristics arising from such changes in antibody sequence.
Before showing the documents to Sports Illustrated, Exum tried to use them in a lawsuit against USOC, accusing the organization of racial discrimination and wrongful termination against him and cover-up over the failed tests. the Denver federal Court summarily dismissed his case for lack of evidence. The USOC labelled his case "baseless" as he himself was the one in charge of screening the anti-doping test program of the organization and clarifying that the athletes were cleared according to the rules. Carl Lewis broke his silence on allegations that he was the beneficiary of a drugs cover-up, admitting he had failed tests for banned substances, but claiming he was just one of "hundreds" of American athletes who were allowed to escape bans, concealed by the USOC. Lewis has acknowledged that he failed three tests during the 1988 US Olympic trials, which under international rules at the time should have prevented him from competing in the 1988 Summer Olympics. Former athletes and officials came out against the USOC cover-up. "For so many years I lived it. I knew this was going on, but there's absolutely nothing you can do as an athlete. You have to believe governing bodies are doing what they are supposed to do. And it is obvious they did not," said former American sprinter and 1984 Olympic champion, Evelyn Ashford. Exum's documents revealed that Carl Lewis had tested positive three times at the 1988 Olympics trials for minimum amounts of pseudoephedrine, ephedrine, and phenylpropanolamine, which were banned stimulants. Bronchodilators are also found in cold medication.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.